Cipla Limited (NSE: CIPLA)
India
· Delayed Price · Currency is INR
1,668.00
+27.30 (1.66%)
Oct 9, 2024, 1:00 PM IST
Cipla Revenue
Cipla had revenue of 66.25B INR in the quarter ending June 30, 2024, with 5.67% growth. This brings the company's revenue in the last twelve months to 258.92B, up 10.13% year-over-year. In the fiscal year ending March 31, 2024, Cipla had annual revenue of 255.37B with 13.20% growth.
Revenue (ttm)
258.92B
Revenue Growth
+10.13%
P/S Ratio
5.05
Revenue / Employee
9.33M
Employees
27,764
Market Cap
1,307.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
Mar 31, 2020 | 170.81B | 7.57B | 4.64% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCipla News
- 1 day ago - Top Nifty Gainers Today: Cipla, Trent, Tata Motors, SBI, Maruti, Tech Mahindra lead the charge - Business Upturn
- 1 day ago - Nifty Pharma hits record high, Divi’s Lab surges 5.83%, Cipla up 1.75% - Business Upturn
- 6 days ago - Stocks hitting lower circuit today: Zee Media, PC Jeweller, Reliance Power and more - Business Upturn
- 6 days ago - Investec maintains Buy call on Cipla, sees 15% upside in share price - Business Upturn
- 7 days ago - JPMorgan maintains ‘Overweight’ on Cipla, expects 30% upside – Check out the target price - Business Upturn
- 10 days ago - No stocks under F&O ban today; Bandhan Bank and RBL Bank close to limits - Business Upturn
- 10 days ago - Stocks to Watch: RIL, Adani Enterprises, BEL, GAIL, Kaynes Technology, Lupin, Jubilant Pharma, Zomato and morein focus today (Sept 30, 2024) - Business Upturn
- 4 weeks ago - Zydus, Cipla, Lupin, Divi’s: Pharma stocks surge after US House of Representatives passes Biosecure Act - Business Upturn